Octreotide acetate in dominant cystoid macular dystrophy.
OBJECTIVE
Dominant cystoid macular degeneration (DCMD) is an autosomal dominant trait of cystoid macular edema with poor visual prognosis. Until now, no efficient treatments for DCMD have been reported. The authors evaluated a somatostatin-analogue (octreotide acetate) as treatment for DCMD.


METHODS
The authors treated four patients with early DCMD by intramuscular longacting octreotide acetate, 20 mg every 4 weeks for 1 year. In addition to general ophthalmologic examination the authors performed fluorescein angiography (FA) before and after treatment.


RESULTS
Seven out of eight eyes showed improvement on FA and stabilization of visual acuity.


CONCLUSIONS
Somatostatin-analogues may reduce cystoid edema in DCMD and may thus prevent disease-related visual loss.
Hogewind
B F
BF
University Medical Centre St Radboud, Nijmegen, Gelderland, The Netherlands. b.hogewind@ohk.umcn.nl
Pieters
G
G
Hoyng
C B
CB
D000293:Adolescent; D000328:Adult; D005260:Female; D005451:Fluorescein Angiography; D005799:Genes, Dominant; D006801:Humans; D007273:Injections, Intramuscular; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
D015282:Octreotide